Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
Date:11/14/2011

, except as required under applicable law.

Conference CallSimcere Pharmaceutical Group will host a conference call to discuss the Company's results for the third quarter of 2011 on Monday, November 14, at 8:00 a.m. Eastern Time (Monday, November 14 at 9:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for the third quarter of 2011 and to answer questions.

To access the conference call, please dial:United States toll-free:

+1.866.519.4004United States toll:

+1.718.354.1231China Domestic:

800.819.0121China Domestic mobile

400.620.8038Hong Kong:

+852.2475.0994Please ask to be connected to Q3 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 21357022.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:  

+1.866.214.5335United States toll:+1.718.354.1232The passcode for replay participants is 21357022. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group ("Simcere") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer,
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
11. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... N.J. , June 19, 2013 /PRNewswire-iReach/ ... Pharma, a new specialty pharmaceutical company dedicated ... of innovative injectable and sustained release drug ... unmet medical needs, today announced the acquisition ... Linker Technology®) platform and associated product pipeline. ...
(Date:6/19/2013)... NEW YORK , June 19, 2013 ... a brand new infographic summary of the results ... Nearly a third of all respondents stated that CROs would ... months. 50% of respondents will be running 6 or more ... association with the Clinical Trial Supply USA ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... Instrument announced the award of two contracts from the ... Evaluation and Research (CDER).  The first award is a ... Warehouse, and the second award supports the expansion of ... Mortara has a long-standing relationship with ...
... Sept. 30 HHS, Agency for Healthcare Research and ... grants and contracts to support projects that will help ... evidence of effectiveness. The funding announced today covers all ... HHS Secretary by AHRQ.   The projects ...
Cached Medicine Technology:Mortara Instrument Announces ECG Warehouse Contract Awards With US FDA 2HHS Awards $473 Million in Patient-Centered Outcomes Research Funding 2
(Date:6/19/2013)... Citi Bike has come to New York City in a big ... for sure how many patients will choose to take advantage of ... In fact, he’s happy about anything that might help his ... convenient for them to visit his office at 133 East 58th ... at Back and Body Medical and an experienced NYC chiropractor ...
(Date:6/19/2013)... KS (PRWEB) June 19, 2013 The ... is common with today’s computer software, it creates questions ... form of misconduct. As an already published case shows, ... photo manipulation. , The Journal of Parasitology ... manipulation in a 2004 article published in the ...
(Date:6/19/2013)... ANGELES (June 19, 2013) In what is believed ... the most common form of hereditary dystonia a ... experts in deep brain stimulation report good success rates ... of the Movement Disorders Program at Cedars-Sinai Medical Center,s ... of the Division of Neurosurgery at Beth Israel Deaconess ...
(Date:6/19/2013)... genetic process that can lead to cervical cancer may ... women, and also raises a warning flag about the ... they could actually trigger the cancer they are trying ... of the chromosomal and genetic changes that take place ... and, in less than 1 percent of cases, to ...
(Date:6/19/2013)... in Spanish . ... it goes by the name of the 10/90 gap: only ... conditions that accounted for 90 per cent of the global ... Drugs for Neglected Diseases initiative (DNDi) came into being in ... been granted the BBVA Foundation Frontiers of Knowledge Award in ...
Breaking Medicine News(10 mins):Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... Scientists know little about how the brain creates and ... obstacle in the effort to develop treatments for emotional ... is in its infancy," says Howard Hughes Medical Institute ... continue to take an enormous toll on human society." ...
... heart risk, leaked documents suggest , SATURDAY, Feb. 20 ... Avandia raises users, odds for heart attack and heart ... to confidential government reports. , The New York ... U.S. Food and Drug Administration that find that if ...
... ... it,s new shop in Beverly Hills, featuring old style barbering, straight razor shaves, in a ... ... today the official opening of its Beverly Hills store located at 9635 Brighton Way, Beverly ...
... ... chief loss mitigator for IndyMac Banks HELOC division, conducted a short sale continuing ... Honish is the first bank employee approved by any state to conduct a ... only course on the subject of short sales taught from this perspective. The ...
... ... ... , ... , ...
... ... ... ... , ...
Cached Medicine News:Health News:David Anderson to discuss what model organisms can teach us about emotion 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 3Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 4Health News:The Classic Shave Company Announces the Opening of Beverly Hills Shop 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 2Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 4Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 5Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: